Eurofins Optimed

At Eurofins Optimed, clinical research in cardiovascular diseases and nutritional and metabolic diseases focuses on understanding how new treatments behave in the body and whether they are safe and well tolerated. The studies also support work in related conditions such as impaired renal function and suspected metabolic dysfunction-associated steatohepatitis, with the goal of improving treatment selection and patient care.

• Testing the safety and body-handling of new therapies in healthy volunteers
• Evaluating treatment effects in metabolic and kidney-related conditions
• Assessing whether candidate medicines may help address complex chronic disease needs

Several trials in this area are designed to build early evidence for future therapies and to better understand how medicines may perform in people with different health profiles.

This site is also active in nervous system diseases and broader neurological disease research, including conditions such as Alzheimer’s disease, Parkinson disease, epilepsy, Dravet syndrome, and primary insomnia. The research aims to explore new treatment options, improve understanding of drug behavior, and support better symptom control.

• Studying potential therapies for neurodegenerative and seizure-related disorders
• Exploring medicines that may improve sleep and neurological symptoms
• Generating early evidence to guide future treatment development

The clinical program also includes work in psychiatric disorder and alcohol use disorder, reflecting a wide interest in brain and behavior-related health challenges.

Research in digestive system diseases includes studies in moderately to severely active ulcerative colitis, with a focus on evaluating whether new medicines may help control inflammation and improve patient outcomes. This area supports the search for better treatment options in chronic gastrointestinal disease.

• Assessing new approaches for inflammatory bowel conditions
• Examining how candidate treatments may reduce disease burden
• Supporting development of improved care strategies for digestive disorders

These trials are aimed at understanding both safety and potential benefit, helping move promising therapies closer to practical use.

Clinical trials at Eurofins Optimed also cover disorders of environmental origin and other acute medical needs, including anaphylaxis and treatment of patients poisoned with organophosphorus compounds. The research is centered on testing antidote and emergency-response therapies that may improve rapid care in urgent situations.

• Evaluating antidote and rescue treatments for poisoning and severe allergic reactions
• Studying how candidate medicines are tolerated in healthy participants
• Building evidence for safer emergency treatment options

This work helps support faster and more effective intervention for high-risk, time-sensitive conditions.

Another important part of the portfolio involves hormonal diseases, pathological conditions, signs and symptoms, and broader clinical pharmacology research. Studies in this area include moderate to severe pain and other symptom-focused conditions, with an emphasis on early testing of new medicines and how the body absorbs and responds to them.

• Investigating symptom relief and treatment effectiveness
• Comparing formulations and bioavailability of medicines
• Supporting first-in-human evaluation of new therapeutic candidates

The research reflects a strong focus on practical drug development questions, especially safety, tolerability, and how different formulations may perform in real-world use.

A large share of the clinical research at Eurofins Optimed involves healthy volunteers, where studies are used to test the safety, tolerability, pharmacokinetics, and bioavailability of new or existing medicines. These trials help determine how treatments are absorbed and whether different product versions behave similarly.

• Testing new medicines in people without the target disease
• Comparing formulations to support bioequivalence and product development
• Evaluating interactions between medicines and their effects on blood levels

This research supports early-stage drug development across multiple therapeutic areas and helps establish a foundation for later clinical use.